Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?
Clin Infect Dis
.
2021 Dec 6;73(11):e3978-e3979.
doi: 10.1093/cid/ciaa1208.
Authors
Sarah C J Jorgensen
1
,
Lisa Burry
1
2
,
Christopher L Y Tse
2
,
Linda D Dresser
2
3
Affiliations
1
Department of Pharmacy, Sinai Health System, Toronto, Ontario, Canada.
2
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
3
Antimicrobial Stewardship Program, University Health Network, Toronto, Ontario, Canada.
PMID:
32797237
PMCID:
PMC7454398
DOI:
10.1093/cid/ciaa1208
No abstract available
Publication types
Letter
Comment
MeSH terms
Azetidines*
COVID-19 Drug Treatment*
Humans
Purines
Pyrazoles
SARS-CoV-2
Sulfonamides
Substances
Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib